Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.

Volume: 34, Issue: 2, Pages: 531 - 538
Published: Jun 12, 2020
Abstract
There is no specific therapy for polyoma BK virus nephropathy (BKVN) in kidney transplant recipients, a condition associated with poor outcomes. Everolimus showed promising antiviral effects, but data from prospective studies are limited. Therefore, we converted ten consecutive kidney transplant recipients with biopsy-proven BKVN from standard exposure Calcineurin inhibitors and Mycophenolate to Everolimus and reduced exposure Calcineurin...
Paper Details
Title
Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
Published Date
Jun 12, 2020
Volume
34
Issue
2
Pages
531 - 538
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.